Corient Private Wealth LP decreased its position in Quest Diagnostics Incorporated (NYSE: DGX) by 13

Fed hikes rates and signals another, putting MGEE, ADM, DOLE and DGX in focus as low-beta defensive

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? W

75% of registered voters surveyed call diagnostic testing "very important" to their care, and a  bip

Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report)'s stock price hit a new 52-week high on

Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript

The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi p

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Coming later this year, Apple Health app users will be able to conveniently and securely purchase an

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the p

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key

Connor Clark and Lunn Investment Management Ltd. purchased a new position in Quest Diagnostics Incor

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Bank OZK purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the second quarte

Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE: DG

SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader i

Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health

Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report)'s share price reached a new 52-week hig

SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader i

Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing sym

Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptom

Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but deb

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? W

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidan

U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11

Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript f

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.63-$10.83 to $11.05-$11.25 vs $

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.12 per share which beat the analyst c

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announce

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the p

Quest Diagnostics (DGX) reported strong Q1 earnings, beating expectations and raising guidance. Anal

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and

Quest Diagnostics Q1 revenue grew 9.2% as organic volume surged. Discover how new partnerships and A

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.4

Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.50-$10.70 to $10.63-$10.83 vs $

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.50 per share which beat the analyst c

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Li